Company
Oxurion is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy, the leading cause of vision loss in elderly people worldwide.
While a lot of companies focused their research based on the genetic origins of AMD (e.g. complement pathway), we decided to tackle the disease from a different angle, focusing mainly on the identification of cytoprotective targets through CRISPR-based target discovery platform.
Our Mission
Our Mission
To prevent blindness by pioneering life changing treatments that address unmet medical needs in ophthalmology, with a focus on retinal diseases including Age-related Macular Degeneration (AMD).
Oxurion is headquartered in Leuven, Belgium, and is listed on Euronext Brussels under the symbol OXUR
Your Vision is Our Vision
We are united by the shared goal of helping people to see better.
Team
Executive Team
Pascal Ghoson
Andy De Deene, MD, MBA
Philippe Barbeaux
Team
BOARD OF DIRECTORS
Charles Paris de Bollardière
James Hartmann
Pascal Ghoson
Nathalie Laarakker, CPA
Dr. Anat Loewenstein, MD, MHA
Let's Talk
To inquire regarding partnership opportunities with Oxurion, please contact: